# Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

> **NCT00181558** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 44 (—)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Atrasentan
- **DRUG:** Zoledronic Acid (Zometa)

## Key facts

- **NCT ID:** NCT00181558
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 44 (—)
- **Last updated:** 2010-05-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181558, "Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00181558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*